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Abstract
Background: Acute upper respiratory tract infections (ARI) in children are quite common and often recurrent.
Overuse of antibiotics must be avoided, and thus herbal remedies are a useful therapeutic option, as most ARIs can
be treated without antibiotics. The aim of this observational study was to demonstrate the effectiveness and
tolerability of the herbal combination preparation Tonsilgon® N in Russian children aged 2–11 years in routine
practice.
Methods: In a prospective, non-interventional study a total of 518 paediatric patients (boys and girls) with ARI
were enrolled at 14 study sites in Russia (2013 - 2014). Patients must have had at least two episodes of ARI in
the last 6 months prior to enrolment (day 1 = visit 1). Tonsilgon® N was given as coated tablets or oral drops in
age-corresponding dosages. Treatment duration was approximately 14 days (day 15 = visit 2) with a subsequent
30-day follow-up period (to day 45).
The effectiveness of the therapy was assessed on the basis of objective symptoms (mucosal hyperemia and
swelling of tonsils; investigator assessment at visits 1 and 2), subjective symptoms (achiness/fatigue, sore throat,
pain in the extremities, headache, loss of appetite, cough, and hoarseness; parents rated and recorded the
subjective symptoms in patient diaries) and responder rate. Further study parameters included time to symptom
resolution, treatment compliance and concomitant medication intake. Adverse drug reactions were recorded to
assess the tolerability.
Results: Patient distribution by age and gender was similar in both age groups (2–5; 6–11 years). The three most
common inclusion diagnoses were nasopharyngitis, pharyngitis or tonsillitis. For these indications, the objective
symptoms hyperemic mucosa and swollen tonsils nearly completely disappeared by visit 2 (range of relief: 93.4 %
to 97.9 % of patients). Most subjective symptoms resolved within 4 days compared to 7 days in previous ARIs.
Overall, a 3-day-shorter time to symptom resolution was achieved. 99.5 % of the patients were treatment
responders, and 97 % tolerated the herbal medicine well or very well. Treatment compliance was very good
(88.2 %).
Conclusions: Tonsilgon® N is a safe and effective treatment of acute upper respiratory tract infections in young
children (aged 2–11 years) and is likely to reduce the duration of symptoms of ARI.
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Background
Upper respiratory tract infections are a common occur-
rence in children. Such infections are a significant
source of illness and pose a substantial economic burden
on health services and society, in general [1]. Since most
of these infections are of viral origin, usefulness of anti-
biotic therapy following recent guidelines on respiratory
tract infections [2, 3] is not an option and overuse of
antibiotic therapy must be avoided anyway. Plant-based
medicines are a therapeutic option, especially because of
their good tolerability. Since over 50 years now, the
phytotherapeutic medicine, Tonsilgon® N (known as
Imupret® N in some countries), is used worldwide to
treat acute and recurrent infections of the respiratory
tract [4]. Tonsilgon® N is an ethanolic-aqueous extract of
seven medicinal plants, namely marshmallow root
(Althaeae radix), chamomile flower (Matricariae flos),
yarrow herb (Millefolii herba), oak bark (Quercus cortex),
walnut leaves (Juglandis folium), horsetail herb (Equiseti
herba), and dandelion herb (Taraxaci herba). These me-
dicinal plants have established pharmacological effects
including immune modulating, antiseptic, antibacterial,
antiviral and anti-inflammatory properties [4, 5].
The respiratory epithelium represents a major portal
of entry for pathogens. Complex defense mechanisms in
this tissue prevent colonization and infection. In vitro
studies with Tonsilgon® N on lung epithelial A549 cells
point to a possible suppression of airway inflammation
through inhibition of IL-8 and hBD-e production in epi-
thelial cells [4]. In addition, Pahl described immunomod-
ulatory effects of Tonsilgon® N on immune cells from
healthy subjects in vitro [6], suggesting a favorable
influence of Tonsilgon® N on the innate and adaptive
immune systems. Furthermore, its effectiveness was dis-
cussed regarding the antioxidant defense system in chil-
dren with chronic tonsillitis [7]. Clinical investigations in
children so far comprised conservative and surgical
treatment of acute and chronic upper respiratory tract
diseases [8], the effectiveness and preventive action in
children with frequent colds [9], as well as the treatment
in viral respiratory infections [10, 11]. Moreover, Drynov
and colleagues [12] studied Tonsilgon® N drops as
prophylaxis for acute respiratory viral infections (ARVI)
and recurrent chronic tonsillitis in children in Russia. A
few years later, in 2008, Berger described the effective-
ness and safety of Tonsilgon® N (drops and coated
tablets) in children in the scope of an observational
study carried out in Germany in 2006-2007 [5]. There-
fore, experiences with Tonsilgon® N in the treatment of
upper respiratory tract infections are generally very good
[13, 14]. Despite the excellent clinical and immuno-
logical findings in these studies, and despite the fact that
the use of this medicine is well known, it is a fact that
the scientific literature contains few reports of its
evidence-based effectiveness and safety in the treatment
of acute upper respiratory tract infections (ARI).
In Russia, the approved indications for Tonsilgon® N
are “acute and chronic diseases of the upper respiratory
tract (tonsillitis, pharyngitis, laryngitis) and preventative
treatment of complications in viral respiratory infections
and as an adjunct to antibiotic therapy for bacterial in-
fections.” The aim of the present observational study
was to demonstrate and document the effectiveness and
safety of Tonsilgon® N in Russian children suffering from
recurrent acute upper respiratory tract infections.
Methods
Study design
A prospective, non-interventional study (NIS) was car-
ried out at 14 study sites (6 university teaching hospitals,
5 outpatient clinics and 3 private medical institutions) in
Russia from March 2013 to February 2014. Included in
the study were a total of 516 paediatric patients (boys
and girls), aged 2–11 years (N = 269 in age group 2–5,
247 in age group 6–11, 2 out of range), with the diagno-
sis acute upper respiratory tract infections (ARI). The
study was conducted following applicable GCP standards
and in accordance with the Declaration of Helsinki in its
most recent version. In addition, as per local practices,
the study was approved by the local Independent Inter-
disciplinary Ethics Committee on Ethical Review for
Clinical Studies and local ECs at those investigational sites
where available. Parent(s) or legal guardians of each child
provided written consent for the child’s participation in
the study. Clinical sites were monitored by clinical moni-
tors of the contracted clinical research organization.
Inclusion criteria: children, aged 2–11 years; acute
upper respiratory tract infections (ARI); physician’s deci-
sion to carry out a therapy with Tonsilgon® N; Informed
Consent (signed by parent(s) or legal guardian). The in-
clusion diagnoses were acute pharyngitis, acute tonsil-
litis, acute laryngitis and tracheitis, acute tracheitis,
acute laryngotracheitis, acute laryngopharyngitis with at
least two ARI episodes in the last 6 months prior to visit
1 (enrolment); previous ARI episodes had to be docu-
mented in the patient source documents.
Exclusion criteria: no Informed Consent available;
bacterial upper respiratory tract infection; antibiotic
therapy at time of visit 1 (enrolment) or necessity for an
antibiotic therapy; symptoms that were present since
more than 3 days.
Study medication and dosage
Tonsilgon® N drops: 5-6 × 10 drops/day (for children
aged 2–5 years) or 5-6 x 15 drops/day (for children aged
6–11 years) or Tonsilgon® N coated tablets: 5-6 × 1
coated tablets/day (for children aged 6–11 years)
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Dosing Schedule: Treatment with the study medica-
tion for about 14 days (day 1 [visit 1] to about day 15
[visit 2]) followed by a follow-up phase lasting 30 days
(to about day 45 [visit 3]) (see Fig. 1). Visit 1 was con-
ducted on-site or as a phone call. Visit 2 took place on-
site and visit 3 took place either on-site or by phone.
Study parameters
The key study parameters were the objective and sub-
jective symptoms, time to resolution (sourced from
recordings made by the parent(s)/legal guardian in the
patient diaries), co-medication, adverse drug reactions
(ADR) and global assessments of the effectiveness
(responder rate) and tolerability.
Assessment of the effectiveness
Treatment effectiveness was derived from the two ob-
jective and seven subjective symptoms, with the change
from visit 1 to visit 2. Objectively assessed symptoms
were mucosal hyperemia and swelling of the tonsils,
which were assessed by a physician. Subjectively assessed
symptoms were achiness/fatigue, loss of appetite, sore
throat, cough, headache, hoarseness, and pain in the ex-
tremities which were assessed by the parent(s)/patient.
Symptoms were rated using the categories “none”,
“mild”, “moderate”, “severe” and “very severe”.
Time to resolution: The time to symptom resolution
(expressed in days) was established for each symptom
on the basis of the recordings made in the patient
diaries.
Responder vs. non-responder: Non-response was de-
fined as the patient having one of the following:
 need for antibiotic treatment due to insufficient
effectiveness of therapy including the study
medication
 worsening of symptoms
 no change in symptoms.
Response was defined as “no need for antibiotic ther-
apy and improvement in symptom course”.
The number of responders was calculated.
Treatment compliance and co-medications
Dose intakes of study medication were noted in the pa-
tient diaries. Co-medications were also noted.
Tolerability assessments
The tolerability of the study medication was assessed on
the basis of adverse drug reactions (ADR) recordings
made by the physicians at visit 2 and visit 3 and through
the recordings entered by the parents/legal guardians
into the patient diaries.
Data and statistical analyses
This study was non-interventional and statistical hypoth-
esis testing was not carried out. Descriptive statistics
were applied and frequencies calculated. Moreover, in
order to detect possible dependencies, a COX propor-
tional hazard model with factors gender, age, compliance
and drug formulation was calculated for the parameter
‘time to resolution of symptoms’. SAS/STAT software
(version 9.2) was used for the statistical analyses [15].
Results and discussion
The distribution of study patients and the acute upper
respiratory tract infections in the 6 months preceding
study enrolment is presented in Table 1. Initially, 518
paediatric patients were enrolled in the study, but 516
patients were included in the final analyses. One male
patient proved to be a screening failure (only 1.8 years
of age), and because there were no data available for this
patient, he was excluded from the final analyses. One fe-
male patient was 12 years of age and so outside the per-
protocol age limit. However, as there were data available
for this patient, she was not included in the group of 6–
11-year-olds but her data were listed separately.
The two patient groups—children aged 2–5 years and
6–11 years, respectively—showed a similar distribution
in terms of the number of boys and girls in each of the
age groups. Unfortunately, two children were inclusion
failures so that in total 131 females (48.7 %) and 138
 - diagnosis   monitoring patient documentation
 - prescription of Tonsilgon N   100% source-data-verification
 - patient enrolment   co-monitoring by sponsor
treatment period follow-up
on-site on-site or phone
Visit 3
day 45
on-site or house call
day 1 day 15
Visit 1 Visit 2
Fig. 1 Flow chart
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males (51.3 %) in the younger group (2–5 years) and 120
females (48.6 %) and 127 males (51.4 %) in the older
group (6–11 years) of patients were evaluated. The
younger group of children made up 52.1 % of the total
study population, while the older group accounted for
47.9 % of the study population (see Table 1).
Regarding the number of previous ARI episodes that
occurred in the 6 months leading up to study enrolment,
most of the children experienced two episodes during
this time, i.e. 79.8 % of the children, while 16.1 % of the
patients experienced three ARI episodes. 3.5 % of the pa-
tients had even four or five episodes (see Table 1).
Protocol violations
There were a total of 96 major protocol violations. They
were defined as follows (number of respective violations
is cited here in brackets): violation of inclusion criteria:
age > 11 years (N = 1), age < 2 years (N = 1); violation of
exclusion criteria: intake of antibacterial drug at visit 1
(N = 13); patient had less than two episodes of acute re-
spiratory viral infection in the 6 months preceding en-
rolment to the study (N = 1); non-compliant dosing
regimens (N = 55), non-compliant concomitant medica-
tion (N = 23), or both (N = 3).
Moreover, there were two patients for whom the num-
ber of ARI prior to enrolment was not recorded. These
two patients were enrolled, but withdrew consent dir-
ectly afterwards, so that there were consequently no
study data available for them.
As mentioned above, two patients did not meet the
age related inclusion criterion. One patient was only
1.8 years old. There were no data for this patient and
therefore the patient was not considered for evaluation.
One further patient was 12 years of age, i.e. older than
the maximal permitted age, and was therefore consid-
ered as another inclusion failure. For this female patient
there were data available. It was decided to list her data,
but to not include them in the analyses. In brief, she
experienced two ARI episodes prior to enrolment, was
diagnosed with an existing laryngotracheitis, her compli-
ance was good and she was classified as a responder.
Her objective symptoms (hyperemic mucosa, swollen
tonsils) were moderate at visit 1 and were no longer
present at visit 2. The subjective symptoms were mild
(loss of appetite, cough, hoarseness and achiness/fatigue)
at the beginning and completely gone at visit 2.
Analyses sets
The full analysis set (FAS) consisted of 516 patients (i.e.
two less than the number of patients enrolled in the
study). The per-protocol set (PPS) consisted of 422 pa-
tients, i.e. all patients without major protocol deviations.
If not otherwise stated, the data presented in the tables
and figures refer to the FAS.
ARI diagnoses at time of enrolment (visit 1)
The study patients were diagnosed with nasopharyngitis,
pharyngitis, tonsillitis, laryngotracheitis, laryngopharyn-
gitis, tracheitis, sinusitis and other (see Fig. 2) at the
time of enrolment. Patients could have more than one
Table 1 Distribution of patients and number of ARI in the last 6 months prior to enrolment
Age
group
Gender N Number of acute upper respiratory tract infections
not recorded once twice three times four times five times
2–5 female 131 2 1 95 27 4 2
male 138 101 28 7 2
6–11 female 120 103 16 1
male 127 113 12 2
Total 516 2 1 412 83 14 4

























































Fig. 2 Frequency of ARI diagnoses
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diagnosis. The two age groups showed a similar distribu-
tion of ARI inclusion diagnoses (see Fig. 3).
Objective symptoms
Upon examination of the study patients, the investiga-
tors assessed the objective symptoms ‘hyperemic mu-
cosa’ and ‘swollen tonsils’ at visit 1 and visit 2. At visit 1,
99 % of the study patients exhibited hyperemic mucosa
and 83 % of the patients had swollen tonsils. The 14-day
treatment achieved substantial relief of both these ob-
jective symptoms. No mucosal hyperemia was observed
in 93 % of the patients at visit 2 and also tonsil swelling
was, at this time, no longer present in 98 % of the
children (N = 516 patients) following the Tonsilgon® N
treatment (see Fig. 4). These findings provide a clear in-
dication of the effectiveness of the herbal medicine.
Further review of the objective symptoms (swollen
tonsils and hyperemic mucosa) at visit 1 and visit 2
shows a clear trend to substantial symptom relief for the
patients with nasopharyngitis, pharyngitis or tonsilli-
tis—the three most common indications present in this
study. Both of the objective symptoms very much im-
proved by visit 2 (see Table 2). For example, of the chil-
dren suffering from nasopharyngitis and who had
hyperemic mucosa at visit 1, N = 339 findings were rated
predominantly as moderate and severe. 316 of these
findings (93.2 %) were no longer present at the time of
visit 2. The same is the case for swollen tonsils: At visit
1, 282 of 339 patients (83 %) had a mild, moderate, se-
vere or very severe swelling of the tonsils. Then, at visit
2, 331 of these 339 findings (97.6 %) were reported as
“none”, i.e. as having resolved in the patients initially di-
agnosed with nasopharyngitis.
In the case of the patients with pharyngitis (N = 151),
the objective symptoms hyperemic mucosa and swollen
tonsils disappeared by visit 2 in the vast majority of
cases. A total of 90.7 % (N = 137) of the finding
hyperemic mucosa totally resolved by visit 2, while tonsil
swelling disappeared in 98.7 % of the cases (N = 149).
Finally, the same trend occurs in the case of the pa-
tients diagnosed with tonsillitis (N = 106). Of the 106
findings of hyperemic mucosa (of mostly moderate se-
verity) at visit 1, 91 (or i.e. 85.8 %) completely resolved
by visit 2. Swollen tonsils (N = 106 patients at visit 1) al-
most disappeared completely after 14 days of treatment
with the study medication (N = 103 or i.e. 97.2 %).
It can be summarized that for the three most common
inclusion diagnoses nasopharyngitis, pharyngitis, and
tonsillitis, the objective symptoms hyperemic mucosa
and swollen tonsils nearly completely disappeared by
visit 2. The extent of relief of these symptoms ranged
from 93.2 % to 98.7 %.
Subjective symptoms
Here the parent(s)/legal guardians were called upon for
their input regarding the subjective symptoms achiness/
fatigue, loss of appetite, sore throat, cough, headache,
hoarseness, and pain in the extremities. These symptoms
and their severity were recorded in the patient diaries.
The respective degrees of severity were described as
“none”, “mild”, “moderate”, “severe”, and “very severe”.
At visit 1, the subjective symptom experienced by the
most patients (approx. 89 %) was achiness/fatigue (see
Fig. 5). This symptom occurred at all levels of severity,
followed closely by loss of appetite (approx. 86 %) and
sore throat (approx. 85 %). Cough was experienced
slightly less frequently, with ratings of mild, moderate,
severe, and very severe reported by the parents in
around 79 % of the cases. Headache was predominantly
























































Fig. 3 Frequency of the three major ARI diagnoses by age group and gender
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the patients experiencing severe or very severe headache.
Overall, this subjective symptom was reported for less
than 60 % of the patients. The least frequent subjective
symptoms reported were hoarseness (around 25 %) and
pain in the extremities in around 21 % of the patients.
The severity of these two subjective symptoms was rated
as being mild, moderate, severe, and very severe, al-
though only around 1.4–3.3 % of the patients com-
plained of severe and very severe hoarseness and pain in
the extremities (see Fig. 5).
After 14 days of treatment with the study medication
when the patients were examined again at visit 2, there
was a dramatic drop in the proportion of patients ex-
periencing subjective symptoms (Fig. 5). All of the symp-
toms had nearly disappeared. Only a very small
proportion of patients still had mild achiness/fatigue and
sore throat (0.78 % each), loss of appetite (approx. 3 %),
cough (mild and moderate severity reported in approx.
3 % of the patients) and hoarseness (mild and moderate
severity; around 0.4 %). Lastly, for all intents and pur-
poses, headache and pain in the extremities completely
disappeared in all 516 patients (FAS) by visit 2.
Time to resolution
The assessment of the ‘time to resolution’ was based on
diary entries of the patients/parent(s). As there was no
continuous observation accompanied by a medical as-
sessment between visit 1 and visit 2, the assessment re-
flects rather the impression of patients/parent(s) and
should not be over-interpreted. Since the duration of
former diseases was assessed retrospectively, these as-
sessments should be handled with care.
The patients’ medical history showed that the mean
time to resolution of the previous ARIs was 7.65 days
(median: 7 days), irrespective of age or gender. Based on
information in the patient diaries, the majority of sub-
jective symptoms resolved within 4 days (median) com-
pared to 7 days in previous ARIs. The exceptions here
are the subjective symptoms cough (median time to
resolution = 6 days) and headache (median time to reso-
lution = 3 days). Data of the time to resolution of the
subjective symptoms underwent a multivariate statistical
analysis using the COX proportional hazard model
which took into account the factors gender, age, compli-
ance, and drug formulation. The factors rarely affected
the time of resolution—an exception was ‘pain in the ex-
tremities’ which was associated with gender (p = 0.0363;
i.e. the symptom lasted longer in boys). Moreover, the
time to resolution of cough (p = 0.0038) and loss of ap-
petite (p = 0.0024) was age-related: The older the child
was, the longer it took for these symptoms to resolve.
Treatment compliance
In this non-interventional study, it was possible to ob-
serve treatment compliance under realistic conditions.
Of the total 516 patients of the FAS, 455 or i.e. 88.2 %
were compliant. Six patients had no treatment compli-
ance data available (see Table 3). In the case of 55 pa-
tients, the reasons for which they were considered non-
compliant were that either the drug dose had been chan-
ged, or the drug intake was irregular or both—i.e. the
drug dose was changed and the intake of the study
medication was irregular. There were slightly more cases
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Fig. 4 Objective symptoms. Proportion of patients by degree of symptom severity and visit
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Table 2 Objective symptom severity at Visit 1 and Visit 2
findings [N] visit 2
visit 1 none mild moderate severe very severe missing
nasopharyngitis hyperemic mucosa none 1 1
mild 37 36 1
moderate 203 193 6 1 1 2
severe 97 85 10 1 1
very severe 1 1
missing
total 339 316 17 2 1 3
swollen tonsils none 57 57
mild 100 98 1 1
moderate 132 128 2 1 1
severe 47 45 1 1
very severe 3 3
missing
total 339 331 4 1 3
pharyngitis hyperemic mucosa none
mild 8 7 1
moderate 76 68 6 1 1
severe 62 57 5
very severe 5 5
missing
total 151 137 12 1 1
swollen tonsils none 18 18
mild 39 38 1
moderate 59 58 1
severe 31 31
very severe 4 4
missing
total 151 149 1 1
tonsillitis hyperemic mucosa none
mild 12 11 1
moderate 67 59 6 1 1
severe 25 19 6
very severe 2 2
missing
total 106 91 13 1 1
swollen tonsils none 1 1
mild 36 35 1
moderate 53 51 1 1
severe 15 15
very severe 1 1
missing
total 106 103 2 1
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patients (2–5 years of age). Of the 55 non-compliant pa-
tients, 29 were in the younger group (2–5 years) and 26
were in the older group of patients (6–11 years). Despite
the non-compliance in 10.7 % of the total 516 cases, by
far the overall majority of patients were compliant. With
a treatment compliance rate of 88.2 %, one can
summarize that the overall treatment compliance in this
study was very good. Moreover, it cannot be ruled out,
that as symptoms improved, the parent(s) decided to
reduce the dosing frequency to 3 times daily, as recom-
mended in the package insert. Therefore, it may be
assumed that the ‘actual patient compliance’ was even
higher.
Concomitant medication
Concomitant medications according to the WHO/DDD
classification had to be recorded by the investigator and
parent(s)/legal guardians (in the patient diaries).
Parallel to the study medication, the types of concomi-
tant medications most reported were preparations for the
respiratory system, e.g. antihistamines, nasal and throat
preparations, drugs for obstructive airway disease and
cough and cold remedies.
Assessment of global effectiveness
Responder rates
A “responder” was defined as a patient in whom the
symptoms resolved completely or were relieved. In the
case of “non-responders”, the patient’s symptoms did
not change, worsened or the patient required antibiotic
therapy. Based on these definitions, nearly all of the
patients (99.5 %) of the PPS—irrespective of age or
gender—were classified as “responders” (see Table 4).
Two patients, who received drops, did not respond to
the phytotherapy. One patient had no change in his/her
symptoms and four patients needed antibiotics.
Tolerability assessment
Analysis of the results of the global tolerability assess-
ments by the investigators and patients/parents revealed
that the treatment was well-tolerated (tolerability rating




































































































Visit 1 Visit 2
N = 516 patients
Fig. 5 Subjective symptoms. Proportion of patients by degree of symptom severity and visit
Table 3 Treatment compliance
Compliance Reasons for non-compliance
Age group Gender yes no not recorded drug dose changed irregular drug intake drug dose changed and irregular intake
2–5 female 113 13 5 13 4
male 121 16 1 12
6–11 female 111 9 7 2
male 110 17 16 1
Total 516 455 55 6 48 5 2
Total [%] 100.0 88.2 10.7 1.2 9.3 1.0 0.4
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“very good”) in the vast majority of cases—for both the
FAS and PPS (see Table 5). These ratings were given by
both the investigators and the patients/parents. In total,
no serious ADR and only one non-serious ADR oc-
curred in one patient in the form of urticaria on the ex-
tremities. It turned out that this patient had a known
history of allergy to Matricaria. The treatment was with-
drawn and no further measures were required. The pa-
tient recovered completely. Moreover, allergy against the
compositae plant family is a known contraindication of
Tonsilgon® N and is stated as such in the package insert.
In summary, Tonsilgon® N (Imupret® N) is a well-
known traditionally used herbal medicine for the treat-
ment of upper respiratory tract infections. Our findings
mirror many of those reported in the literature. For ex-
ample, as reported by Drynov and colleagues [12], Ton-
silgon® N was effective for the treatment of acute
respiratory viral infection and chronic recurrent tonsil-
litis in 32 paediatric patients, aged 3–15 years. A 6-
month treatment with the liquid drug presentation
(drops) resulted in substantial symptom improvement
even 1 year after treatment start. In addition, these au-
thors showed a good correlation between the clinical
findings and the patients’ IgG values.
Further proof of effectiveness and tolerability of the
herbal preparation is clear from the results obtained in
the 2006-2007 German observational study of Tonsil-
gon® N in children with acute respiratory infections [5].
Our findings confirm those reported by Berger, who
demonstrated the medication’s effectiveness and safety
in over 1100 children, aged 2–17 years, with recurring
upper respiratory tract infections. Berger also described
the immunomodulatory and antibacterial properties of
the herbal combination preparation as well as its useful-
ness in relieving symptoms of inflammation.
In the present study, treatment with Tonsilgon® N
achieved nearly complete resolution of symptoms and a
3-day-shorter duration of the illness compared to the
course of preceding ARIs, according to the entries about
previous ARIs in patient medical documents. The study
medication was also well-tolerated and it may be noted
that the availability of the medicine in coated tablet form
as well as in a liquid presentation (drops) makes dosing
easy and convenient for young patients.
Conclusions
It can be concluded that the herbal combination medi-
cine, Tonsilgon® N, is a safe and effective treatment of
acute upper respiratory tract infections in young chil-
dren (aged 2–11 years) and is likely to reduce the dur-
ation of symptoms of ARI. Such clinical outcome
benefits not only the patients and their families, but in-
deed may also relieve the time and financial burden on
health care services.
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PPS Responder Non-Responder Total Responder
(N = 422) N N N [%]
Total 420 2 422 99.5
Age group 2–5 204 2 206 99.0
Age group 6–11 216 216 100.0
Females 210 1 211 99.5
Males 210 1 211 99.5
Table 5 Tolerability assessment
FAS (N = 516 a) PPS (N = 422)
Patient/parents Investigator Patient/parents Investigator
N % N % N % N %
poor 1 0.2 1 0.2 0 0.0 0 0.0
moderate 2 0.4 13 2.5 1 0.2 9 2.1
good 262 50.8 262 50.8 227 53.8 223 52.8
very good 246 47.7 235 45.5 194 46.0 190 45.0
aN = 5 not recorded
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